457_572 - Phase 1/2 clinical trial results announced for PSMA-targeted prostate cancer treatment candidate ‘177Lu-pocuvotide’ 1070_1124 1477_1496 1533_1981 1990_2478 2487_3141 3150_3901 3910_4395 4404_4714 4723_5026